Ardsley Advisory Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ardsley Advisory Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-833	Closed	-$300K	–	167
2018 Q3	$300K	Hold	833	–	–	0.04%	128
2018 Q2	$305K	Buy	+833	New	+$297K	0.05%	135

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ardsley Advisory Partners's EIGR Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 833 shares — an estimated $300K sold.

Ardsley Advisory Partners first reported a position in EIGR in Q2 2018 and held it in 2 quarters. The position peaked at $305K in Q2 2018. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

Ardsley Advisory Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 833 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $300K.
Ardsley Advisory Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
Ardsley Advisory Partners's Eiger BioPharmaceuticals, Inc. position peaked at $305K in Q2 2018.
68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.